NCT06209736: An ongoing trial by Omeros Corporation
This trial is ongoing. It must report results 1 year, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06209736 |
|---|---|
| Title | A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 1, 2024 |
| Completion date | Jan. 31, 2026 |
| Required reporting date | Jan. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |